Guitarist Jack Simmons unpacks his wild ESP refinish, why pinch harmonic riffs are the best riffs, and how he grabbed Ronnie ...

Viking Therapeutics ( ($VKTX) ) has risen by 7.76%. Read on to learn why. Viking Therapeutics has seen a notable 7.76% ...

Viking Therapeutics reported a solid financial standing with $808 million in cash, cash equivalents, and short-term investments. This strong cash position provides a substantial financial runway to ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $30.0 and $60.0 for Viking Therapeutics, spanning the last three ...

That being said, we’re here with a list of the 10 most profitable new stocks to buy now. We sifted through the Finviz stock screener to compile a list of the top companies that went public in the last ...

Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...

CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, ...

Brian Lian, President and CEO, reported that "the Viking team continued to focus on execution of our core clinical strategy," emphasizing advancement of both oral and subcutaneous VK2735 programs. "We ...

Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the ...

Investing.com -- Viking Therapeutics, Inc. (NASDAQ: VKTX) reported a wider-than-expected second quarter loss on Wednesday, sending shares down 4.2% as investors reacted to the earnings miss despite ...

Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...